Transforming growth factor-β isoforms expressions in pulmonary adenocarcinomas as prognostic markers

Oncology (Switzerland)

Volumn 54, Issue 2, 1997, Pages 122-128

  Takanami, Iwao ^a   Tanaka, Fumihiko ^a   Hashizume, Toshinori ^b   Kikuchi, Keiichi ^b   Yamamoto, Yasuki ^a   Yamamoto, Tatsuya ^a   Kodaira, Susumu ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kanagawa National Hospital   (Japan)

Author keywords

Adenocarcinoma; Immunohistochemical staining; Isoforms; Pulmonary; TGF 1; TGF 2; TGF 3

Indexed keywords

ISOPROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ISOMERISM; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 0031051964     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227675     Document Type: Article

References (21)

1. Massague J: The transforming growth t'actor-fi family, Annu Rev Cell Biol 1990;6:597-641.
2. Sporn MB, Roberts AB: Transforming growth factor-p: Recent progress and new challenges, J Cell Biol 1992;119:1017-1021.
3. Dcryneck R, Jarret JA, Chen EY, et al: Human transforming growth factor-p complementary DNA sequences and expression in normal and transformed cells, Nature 1985;316:701-705.
4. Knabbe C, Lippman ME, Wakenfield LM, et al: Evidence that transforming growth factor-p is a hormonally regulated negative growth factor in human breast cancer cells, Cell 1987:48: 417-428.
5. Travis WD, Travis LB, Devesa SS: Lung cancer, Cancer 1995:75:191-202.
6. Varaitis J, Warren S, Gamble D: Increasing incidence of the lung, Cancer 1981;41:1042-1047.
7. Millor DA, Pelton RW, Derrynck R, Moses HL: Transforming growth factor B: A family of growth regulatory peptides, Ann NY Acad Sci 1990;593:208-217.
8. Hirayama D, Fujimomi K, Satonaka K, et al: Immunohistochemical study of epidermal growth factor and transforming growth factor-P in the penetrating type of early gastric cancer, Hum Pathol 1992:23:681-685.
9. Jasani B, Wyllic FS, Wright PA, Lemoine NR, Williams ED, Wynford-Thomas D: Immuno-histochcmically detectable TGF-P is associated with malignancy in thyroid epithelial neoplasia, Growth Factors 1990;2:149-155.
10. Johnson MD, Fcdcrspicl CF, Gold LI, Moses HL: Transforming growth factor-P and transforming growth factor p receptor expression in human meningioma cell, Am J Pathol 1992; 141:633-642.
11. Gorsh SM, Memoli VA, Stukel TA, Gold LI, Arrick BA: Immunohistochemical staining for transforming growth pi associates with disease progression in human breast cancer, Cancer Res 1992;52:6949-6952.
12. Steiner MS, Barrack ER: Transforming growth factor-p 1 overproduction in prostate cancer: Effects on growth in vivo and in vitro, Mol Endocrinol 1992;6:15-25.
13. Shirai Y, Kawata S, Tamura S, et al: Plasma transforming growth factor-P I in patients with hepatocellular carcinoma, Cancer 1994:73: 2275-2279.
14. Friess H, Yamanaka Y, Buchler M, et al: Enhanced expression of transforming growth factor p isoforms in pancreatic cancer correlates with decreased survival, Gastroenterology 1993:105:1846-1856.
15. Czarniecki CW, Chiu HH, Wong GH, McCabe SM, Paladino MA: Transforming growth fac-tor-pl modulates the expression of class II histocompatibility antigens of human cells, J Immunol 1988:140:4217-4223.
16. Grayar JL, Miller DA, Arrie BA, Lyons RM, Moses HL, Derynck R: Human transforming growth factor-P3: Recombinant expression, purification and biological activities in comparison with transforming growth factors pi and p2, Mol Endocrinol 1989:3:1977-1989.
17. Reed JA, McNutt NS, Prieto VG, Albino AP: Expression of transforming growth factor-p2 in malignant melanoma correlates with the depth of tumor invasion, Am J Pathol 1994; 145:97-104.
18. Sorensen JB, Badsberg JH: Prognostic factors in resected stages I and II adenocarcinoma of the lung: A multivariate regression analysis of 137 consecutive patients, J Thorac Cardiovasc Surg 1990:99:218-226.
19. Lanzotti VJ, Thomas DR, Boyle LE, Smith TL, Gehan EA, Samuels ML: Survival with inoperable lung cancer: An integration of prognostic variables based on simple clinical criteria, Cancer 1977;39:303-313.
20. Hara N, Ohta M, Ichinose Y: Surgical adjuvant chemotherapy for lung cancer: in Ishigami J (ed): Recent Advances in Chemotherapy: Proceedings of the 14th International Congress on Chemotherapy, Tokyo, University of Tokyo Press, 1985, pp 155-157.
21. Friess H, Yamanaka Y, Buchler M, et al: Enhanced expression of type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration type III receptor expression, Cancer Res 1993:53:2704-2707.